File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
  • Basic View
  • Metadata View
  • XML View
TitleSARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
 
AuthorsWoo, PCY4 1
Lau, SKP4 1
Tsoi, HW1
Chen, ZW2
Wong, BHL1
Zhang, L2
Chan, JKH1
Wong, LP1
He, W3
Ma, C3
Chan, KH4 1
Ho, DD2
Yuen, KY4 1
 
Issue Date2005
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2005, v. 23 n. 42, p. 4959-4968 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2005.05.023
 
AbstractDifferent forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. © 2005 Elsevier Ltd. All rights reserved.
 
ISSN0264-410X
2013 Impact Factor: 3.485
 
DOIhttp://dx.doi.org/10.1016/j.vaccine.2005.05.023
 
ISI Accession Number IDWOS:000232265200001
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWoo, PCY
 
dc.contributor.authorLau, SKP
 
dc.contributor.authorTsoi, HW
 
dc.contributor.authorChen, ZW
 
dc.contributor.authorWong, BHL
 
dc.contributor.authorZhang, L
 
dc.contributor.authorChan, JKH
 
dc.contributor.authorWong, LP
 
dc.contributor.authorHe, W
 
dc.contributor.authorMa, C
 
dc.contributor.authorChan, KH
 
dc.contributor.authorHo, DD
 
dc.contributor.authorYuen, KY
 
dc.date.accessioned2010-09-06T07:53:06Z
 
dc.date.available2010-09-06T07:53:06Z
 
dc.date.issued2005
 
dc.description.abstractDifferent forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. © 2005 Elsevier Ltd. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2005, v. 23 n. 42, p. 4959-4968 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2005.05.023
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2005.05.023
 
dc.identifier.epage4968
 
dc.identifier.hkuros114672
 
dc.identifier.isiWOS:000232265200001
 
dc.identifier.issn0264-410X
2013 Impact Factor: 3.485
 
dc.identifier.issue42
 
dc.identifier.openurl
 
dc.identifier.pmid15993989
 
dc.identifier.scopuseid_2-s2.0-24644485207
 
dc.identifier.spage4959
 
dc.identifier.urihttp://hdl.handle.net/10722/79306
 
dc.identifier.volume23
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.referencesReferences in Scopus
 
dc.rightsVaccine. Copyright © Elsevier Ltd.
 
dc.subject.meshAdministration, Oral
 
dc.subject.meshAnimals
 
dc.subject.meshAntibodies, Viral - blood - immunology
 
dc.subject.meshBacterial Vaccines - administration & dosage - immunology
 
dc.subject.meshEscherichia coli Proteins
 
dc.subject.meshImmunization Schedule
 
dc.subject.meshImmunization, Secondary
 
dc.subject.meshImmunoglobulin G - blood
 
dc.subject.meshInjections, Intramuscular
 
dc.subject.meshInjections, Intraperitoneal
 
dc.subject.meshInterferon-gamma - analysis
 
dc.subject.meshInterleukin-4 - analysis
 
dc.subject.meshMale
 
dc.subject.meshMembrane Glycoproteins - administration & dosage - genetics - immunology
 
dc.subject.meshMice
 
dc.subject.meshMice, Inbred BALB C
 
dc.subject.meshModels, Animal
 
dc.subject.meshNeutralization Tests
 
dc.subject.meshSARS Virus - immunology
 
dc.subject.meshSevere Acute Respiratory Syndrome - prevention & control
 
dc.subject.meshVaccines, DNA - administration & dosage - immunology
 
dc.subject.meshVaccines, Synthetic - administration & dosage - immunology
 
dc.subject.meshViral Envelope Proteins - administration & dosage - genetics - immunology
 
dc.titleSARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Woo, PCY</contributor.author>
<contributor.author>Lau, SKP</contributor.author>
<contributor.author>Tsoi, HW</contributor.author>
<contributor.author>Chen, ZW</contributor.author>
<contributor.author>Wong, BHL</contributor.author>
<contributor.author>Zhang, L</contributor.author>
<contributor.author>Chan, JKH</contributor.author>
<contributor.author>Wong, LP</contributor.author>
<contributor.author>He, W</contributor.author>
<contributor.author>Ma, C</contributor.author>
<contributor.author>Chan, KH</contributor.author>
<contributor.author>Ho, DD</contributor.author>
<contributor.author>Yuen, KY</contributor.author>
<date.accessioned>2010-09-06T07:53:06Z</date.accessioned>
<date.available>2010-09-06T07:53:06Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Vaccine, 2005, v. 23 n. 42, p. 4959-4968</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/79306</identifier.uri>
<description.abstract>Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of &lt;1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of &#8805;1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. &#169; 2005 Elsevier Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<rights>Vaccine. Copyright &#169; Elsevier Ltd.</rights>
<subject.mesh>Administration, Oral</subject.mesh>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Antibodies, Viral - blood - immunology</subject.mesh>
<subject.mesh>Bacterial Vaccines - administration &amp; dosage - immunology</subject.mesh>
<subject.mesh>Escherichia coli Proteins</subject.mesh>
<subject.mesh>Immunization Schedule</subject.mesh>
<subject.mesh>Immunization, Secondary</subject.mesh>
<subject.mesh>Immunoglobulin G - blood</subject.mesh>
<subject.mesh>Injections, Intramuscular</subject.mesh>
<subject.mesh>Injections, Intraperitoneal</subject.mesh>
<subject.mesh>Interferon-gamma - analysis</subject.mesh>
<subject.mesh>Interleukin-4 - analysis</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Membrane Glycoproteins - administration &amp; dosage - genetics - immunology</subject.mesh>
<subject.mesh>Mice</subject.mesh>
<subject.mesh>Mice, Inbred BALB C</subject.mesh>
<subject.mesh>Models, Animal</subject.mesh>
<subject.mesh>Neutralization Tests</subject.mesh>
<subject.mesh>SARS Virus - immunology</subject.mesh>
<subject.mesh>Severe Acute Respiratory Syndrome - prevention &amp; control</subject.mesh>
<subject.mesh>Vaccines, DNA - administration &amp; dosage - immunology</subject.mesh>
<subject.mesh>Vaccines, Synthetic - administration &amp; dosage - immunology</subject.mesh>
<subject.mesh>Viral Envelope Proteins - administration &amp; dosage - genetics - immunology</subject.mesh>
<title>SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0264-410X&amp;volume=23&amp;spage=4959&amp;epage=4968&amp;date=2005&amp;atitle=SARS+coronavirus+spike+polypeptide+DNA+vaccine+priming+with+recombinant+spike+polypeptide+from+Escherichia+coli+as+booster+induces+high+titer+of+neutralizing+antibody+against+SARS+coronavirus</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.vaccine.2005.05.023</identifier.doi>
<identifier.pmid>15993989</identifier.pmid>
<identifier.scopus>eid_2-s2.0-24644485207</identifier.scopus>
<identifier.hkuros>114672</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-24644485207&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>23</identifier.volume>
<identifier.issue>42</identifier.issue>
<identifier.spage>4959</identifier.spage>
<identifier.epage>4968</identifier.epage>
<identifier.isi>WOS:000232265200001</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Aaron Diamond AIDS Research Center
  3. Peking Union Medical College
  4. Faculty of Medicine